Product Data Sheet

Product Name: Voxvoganan
Cat. No.: GC70126

Chemical Properties

Cas. No.	1166254-80-3		
Formula	$C_{43}H_{69}N_{11}O_3$	M.Wt	788.08
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	Voxvoganan		

Background

Voxvoganan (LTX-109), a topical **antimicrobial**, is highly effective against *S. aureus* with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of fungal infections and nasal decolonisation of MRSA[1][2].

Voxvoganan (LTX-109) is an investigational antimicrobial agent with a membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. Voxvoganan has a rapid bactericidal lytic activity. Voxvoganan demonstrates in vitro bactericidal activity against a number of *S. aureus* isolates resistant to several classes of antimicrobial agents evaluated in this study[2].
Voxvoganan (LTX-109) is a broad-spectrum, fast-acting bactericidal antimicrobial agent that binds to negatively charged membrane components on the bacterial cell wall, which leads to membrane disruption and cell lysis. Voxvoganan is a first-in-class chemically synthesized, small peptide drug that is stable against protease degradation. Topical application of Voxvoganan has a good safety profile and a low bioavailability. Voxvoganan demonstrates good activity against *Staplococcus aureus* strains that are susceptible and resistant to mupirocin[3].

[1]. Johan Isaksson, et al. A synthetic antimicrobial peptidomimetic (LTX 109):

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
[2]. Louis D Saravolatz, et al. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staplococcus aureus. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82.
[3]. L D Saravolatz, et al. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staplococcus aureus blood isolates. Lett Appl Microbiol. 2017 Nov;65(5):410-413.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA